Details
Stereochemistry | ACHIRAL |
Molecular Formula | CH5N3 |
Molecular Weight | 59.0705 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(N)=N
InChI
InChIKey=ZRALSGWEFCBTJO-UHFFFAOYSA-N
InChI=1S/CH5N3/c2-1(3)4/h(H5,2,3,4)
Molecular Formula | CH5N3 |
Molecular Weight | 59.0705 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10973602
Curator's Comment: The study was performed on rats.
Originator
Sources: https://d-nb.info/1059797615/34
Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362996 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21926190 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | GUANIDINE HYDROCHLORIDE Approved UseGuanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis. Launch Date1939 |
PubMed
Title | Date | PubMed |
---|---|---|
The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. | 2001 |
|
Topological diversity of artificial beta-barrels in water. | 2001 |
|
Dihydrofolate reductase from Thermotoga maritima. | 2001 |
|
Total chemical synthesis of human matrix Gla protein. | 2001 Apr |
|
The structure of human mitochondrial branched-chain aminotransferase. | 2001 Apr |
|
High-sensitivity fluorescence anisotropy detection of protein-folding events: application to alpha-lactalbumin. | 2001 Apr |
|
Guanidine-induced equilibrium unfolding of a homo-hexameric enzyme 4-oxalocrotonate tautomerase (4-OT). | 2001 Apr 10 |
|
Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent. | 2001 Apr 12 |
|
Structure--function relationships in bovine thymus 20S proteasome: a fluorimetric study. | 2001 Apr 12 |
|
Characterization of the denatured states distribution of neocarzinostatin by small-angle neutron scattering and differential scanning calorimetry. | 2001 Apr 3 |
|
Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes. | 2001 Feb |
|
Stabilization of hen egg white lysozyme by a cavity-filling mutation. | 2001 Feb |
|
Metric engineering of soft molecular host frameworks. | 2001 Feb |
|
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor. | 2001 Feb |
|
Specific neosaxitoxin interactions with the Na+ channel outer vestibule determined by mutant cycle analysis. | 2001 Feb |
|
Apparent two-state tendamistat folding is a sequential process along a defined route. | 2001 Feb 16 |
|
Spontaneous and flow-induced Ca2+ transients in retracted regions in endothelial cells. | 2001 Feb 16 |
|
Solid-phase guanidinylation as a diversification strategy of poly-L-proline type II peptide mimic scaffolds. | 2001 Feb 22 |
|
Uracil moiety is required for toxicity of the cyanobacterial hepatotoxin cylindrospermopsin. | 2001 Feb 23 |
|
Dichlorobis(glycocyamine-O)copper(II). | 2001 Jan |
|
Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates. | 2001 Jan 1 |
|
The influence of ATP on the association and unfolding of the tyrosine repressor ligand response domain of Haemophilus influenzae. | 2001 Jan 12 |
|
Achieving stability and conformational specificity in designed proteins via binary patterning. | 2001 Jan 19 |
|
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp. | 2001 Jan 23 |
|
[Y97V substitution in the horse cytochrome c causes accumulation of the equilibrium intermediate]. | 2001 Jan-Feb |
|
[Antibody avidity: use for the diagnosis of HIV early infection]. | 2001 Jan-Feb |
|
A rigid linker-scaffold for solid-phase synthesis of dimeric pharmacophores. | 2001 Jan-Feb |
|
Protein compactness measured by fluorescence resonance energy transfer. Human carbonic anhydrase ii is considerably expanded by the interaction of GroEL. | 2001 Jun 15 |
|
alpha Arg-237 in Methylophilus methylotrophus (sp. W3A1) electron-transferring flavoprotein affords approximately 200-millivolt stabilization of the FAD anionic semiquinone and a kinetic block on full reduction to the dihydroquinone. | 2001 Jun 8 |
|
Elucidation of a [4Fe-4S] cluster degradation pathway: rapid kinetic studies of the degradation of Chromatium vinosum HiPIP. | 2001 Mar |
|
Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride. | 2001 Mar |
|
Characterization of carbonic anhydrase from Neisseria gonorrhoeae. | 2001 Mar |
|
Structure-activity relationship of the p55 TNF receptor death domain and its lymphoproliferation mutants. | 2001 Mar |
|
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. | 2001 Mar |
|
Cutinase unfolding and stabilization by trehalose and mannosylglycerate. | 2001 Mar 1 |
|
Major differences in stability and dimerization properties of two chimeric mutants of human stefins. | 2001 Mar 1 |
|
The synthesis of beta-peptides containing guanidino groups. | 2001 Mar 12 |
|
An N-terminal three-helix fragment of the exchangeable insect apolipoprotein apolipophorin III conserves the lipid binding properties of wild-type protein. | 2001 Mar 13 |
|
Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. | 2001 Mar 15 |
|
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. | 2001 Mar 15 |
|
Matrix proteins from insect pliable cuticles: are they flexible and easily deformed? | 2001 Mar 15 |
|
Probing local conformational changes during equilibrium unfolding of firefly luciferase: fluorescence and circular dichroism studies of single tryptophan mutants. | 2001 Mar 23 |
|
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states. | 2001 Mar 30 |
|
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. | 2001 Mar 30 |
|
Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation. | 2001 Mar 9 |
|
Proton and metal ion-dependent assembly of a model diiron protein. | 2001 May |
|
Cyclic green fluorescent protein produced in vivo using an artificially split PI-PfuI intein from Pyrococcus furiosus. | 2001 May 11 |
|
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. | 2001 May 15 |
|
Replacement of thrombin residue G184 with Lys or Arg fails to mimic Na+ binding. | 2001 May 15 |
|
Folding intermediates of a model three-helix bundle protein. Pressure and cold denaturation studies. | 2001 May 4 |
Sample Use Guides
Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2135950
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:25 GMT 2025
by
admin
on
Mon Mar 31 18:06:25 GMT 2025
|
Record UNII |
JU58VJ6Y3B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C45564
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
||
|
NDF-RT |
N0000175772
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
||
|
NDF-RT |
N0000009079
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID0023117
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
DB00536
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
113-00-8
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
50675
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
D019791
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
SUB14034MIG
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
C77851
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
7603
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
m5867
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
30087
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
204-021-8
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
JU58VJ6Y3B
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
GUANIDINE
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
4783
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
1344
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
100000077877
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
42820
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY | |||
|
3520
Created by
admin on Mon Mar 31 18:06:25 GMT 2025 , Edited by admin on Mon Mar 31 18:06:25 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
Vmax
|
||
|
TRANSPORTER -> SUBSTRATE |
Km
|
||
|
TRANSPORTER -> SUBSTRATE |
Km
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE |
Vmax
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|